Krabbe diseases is achieved by measurement of the lysosomal enzymes acid sphingomyelinase (ASM) and galactocerebroside ␤-galactosidase (GCG), respectively. Conventional assays use radiolabeled or fluorescent substrates and do not allow simultaneous determination of two or more enzymes in the sample. Methods: We developed a sensitive and specific method to assay ASM and GCG in skin fibroblast homogenates using biotinylated substrate conjugates. The products were purified by bioaffinity capture on streptavidinagarose beads and, following release, were analyzed by electrospray ionization mass spectrometry. Quantification was achieved using stable-isotope-labeled internal standards that were chemically identical to the products of the enzymatic reactions. Results: The method demonstrated excellent linearity of ASM and GCG enzymatic product formation with the amount of cellular protein and incubation time. The range of ASM activities in fibroblast lysates from six healthy patients was 39 -70 nmol ⅐ mg ؊1 ⅐ h ؊1 compared with 3.7-5.1 nmol ⅐ mg ؊1 ⅐ h ؊1 in cell lysates from two patients affected with Niemann-Pick A disease. The GCG activities toward the corresponding substrate conjugate were 4.0 -6.8 nmol ⅐ mg ؊1 ⅐ h ؊1 in cell lysates from healthy patients compared with 0.1-0.2 nmol ⅐ mg ؊1 ⅐ h ؊1 in cell lysates from two patients affected with Krabbe disease. The amounts of substrate conjugates needed per analysis were 15 nmol (14 g) for both ASM and GCG.
the molecular mass of the product, which is detected by mass spectrometry following electrospray ionization.
A key feature for rapid analysis is the presence in the substrate conjugate, and thus in the product, of a biotin moiety (molecular handle) that allows specific capture by streptavidin immobilized on agarose beads; nonbiotinylated species can then be removed by simple washing. This approach avoids tedious purification by chromatography and has the potential for automation. Another key feature pertinent to quantification by mass spectrometry is the use of internal standards labeled with stable isotopes ( 2 H, 13 C, or a combination thereof). The internal standards are chemically identical to the products of the enzymatic reactions but differ in molecular mass as a result of the presence of heavy isotopes. The internal standards are added at the end of the enzymatic reaction. After affinity capture of biotinylated conjugates and clean-up by multiple washings, the biotinylated conjugates are displaced from the beads with excess free biotin, and the final wash solution is directly analyzed by ESI-MS.
The advantages of using ESI-MS are several-fold. One advantage is that ESI is a gentle ionization method that typically does not lead to fragmentation of gas-phase ions (11 ) . The information obtained from ESI-MS therefore relates to the intact molecules of the analyte that appear as cations with m/z values corresponding to that of the analyte plus that of the charge-introducing particle, which typically is a proton or a sodium cation. Analysis in the negative-ion mode is also possible if dictated by the chemical nature of the conjugate. Another advantage is that ESI-MS as a rule provides excellent detection limits, often in the low femtomole (10 Ϫ15 mol) to attomole (10 Ϫ18 mol) range. Finally, the m/z values are highly indicative of the analyte species, in particular when coupled with an isotopically labeled derivative of known mass difference.
Materials and Methods materials
Sphingosylphosphoryl choline (ϳ85%), psychosine, Triton X-100, sodium taurocholate, and oleic acid were purchased from Sigma. Human skin fibroblasts from two patients with Niemann-Pick disease and two with Krabbe disease, repository numbers GM00406, GM00370, GM04517, and GM04372, were obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ).
These cells as well as fibroblasts from six healthy persons were cultured according to standard procedures (14 ) and stored at Ϫ80°C.
substrate conjugates and internal standards
The substrate conjugates for ASM and GCG consisted of similar building blocks (schemes 2 and 3). Biotin was conjugated to a sarcosine linker that served two functions: (a) it provided the moiety for stable-isotope introduction in the synthesis of internal standards, and (b) it blocked the action of the enzyme biotinidase (15 ) , which is present in biological fluids and could cleave the biotin handle off the product conjugates. Sarcosine was further conjugated to 12-aminododecanoic acid (for ASM) or 11-aminoundecanoic acid (for GCG) linkers that mimicked the hydrophobic chain in the natural sphingomyelin or cerebroside substrates (7 ) . The different linker chain lengths for ASM and GCG were chosen to offset the molecular masses of the products and internal standards and to allow simultaneous assay of both enzymes in one sample. The carboxylic acid groups provided the functionalities for coupling to the amino group in the sphingosine moiety. The chemical coupling of the handle, linker, and substrate parts was achieved through stable amide bonds to ensure chemical and enzymatic stability of the substrate conjugates and products. The chemical syntheses of the substrate conjugates and internal standards labeled with stable isotopes are described below.
ASM cleaved the choline moiety and reduced the molecular mass of the substrate conjugate from 958.6 Da to that of the product (793.6 Da). This change was readily detected by ESI-MS as the corresponding (M ϩ H) ϩ ions at m/z 959.7 and 794.6, respectively (scheme 2). The internal standard was shifted by 4 mass units as a result of the presence of the 2 H and 13 C labels in the sarcosine linker. The stable isotopes were introduced in positions that do not undergo exchange with solvent or reagents, ensuring chemical homogeneity of the internal standard. Likewise, GCG cleaved galactose and reduced the molecular mass of the substrate conjugate from 941.6 Da to that of the product (779.6 Da). The reaction progress was monitored by the appearance of the (M ϩ H) ϩ ion of the product at m/z 780.6 and quantified by the peak of the internal standard at m/z 784.6 (scheme 3).
synthetic procedures
Biotin tetrafluorophenyl ester (1) . Biotin (2.0 g; 8.18 mmol) was dissolved in 40 mL of warm (60°C) N,N-dimethylformamide (DMF) under argon atmosphere. After the solution cooled to room temperature, 2 mL (14.3 mmol) of triethylamine was added, followed by 3.2 g (12.2 mmol) of 2,3,5,6-tetrafluorophenyl trifluoroacetate (12 ) . The reaction was stirred at room temperature for 30 min, and the solvent was removed under reduced pressure. The product was triturated with 100 mL of ether and filtered. The isolated product was dried under reduced pressure to yield 2. (2) . Biotin tetrafluorophenyl ester (1.00 g; 2.55 mmol) in 10 mL of anhydrous DMF under argon atmosphere was added to a mixture of 0.482 g (3.45 mmol) of N-methylglycine methyl ester hydrochloride dissolved in 5 mL of anhydrous DMF and 0.5 mL (3.59 mmol) of triethylamine. The reaction mixture was stirred at room temperature for 2 h, and the solvent was removed under reduced pressure. The residue was extracted with chloroform (twice with 40 mL each time), washed with water (twice with 10 mL each time), and dried with anhydrous sodium sulfate. The solvent was removed under reduced pressure to yield 0.801 g (95%) of (3). Ester 2 (0.801 g; 2.43 mmol) was hydrolyzed in a mixture containing 15 mL of methanol and 10 mL of 2 mol/L NaOH at room temperature with stirring for 2 h. The mixture was diluted with 20 mL of methanol-H 2 O (50:50 by volume) and neutralized with a cation-exchange resin (AG MP-50 Resin, H ϩ form). The solution was filtered, and the resin was washed with methanol-H 2 O (50:50 by volume). The solutions were combined, and the combined solvent was removed under reduced pressure to yield 0.620 g (80.8%) of compound 3. (4) . Compound 3 (95.6 mg; 0.3 mmol) was dried under reduced pressure overnight. Dry DMF (4 mL) was added, and the mixture was stirred with mild heating for 10 min. Freshly distilled triethylamine (100.3 L) was then added, followed after 3 min by 32 L of tetrafluorophenyl trifluoroacetate. Another 32 L of tetrafluorophenyl trifluoroacetate was added after a 5-min interval. The mixture was stirred for 1 h under argon. Thin-layer chromatographic analysis showed formation of the tetrafluorophenyl ester 4 (R f 0.5; mobile phase, CHCl 3 -methanol, 9:1 by volume).
N-Methyl-N-biotinylglycine methyl ester

N-Methyl-N-biotinylglycine
N-Methyl-N-biotinylglycine tetrafluorophenyl ester
N-(NЈ-Methyl-NЈ-biotinylglycyl)12-aminododecanoic acid (5a).
To the solution of 4 in DMF was added 77.5 mg (0.36 mmol) of 12-aminododecanoic acid in 4 mL of DMF, and the mixture was stirred at room temperature for 2 h. Chloroform (100 mL) was added, and the solution was washed with 20 mL of 1 mol/L HCl and brine and then dried with sodium sulfate. The solvent was removed, and the residue was redissolved in methanol and purified by HPLC (protein & peptide C 18 column; cat. no. 218TP1022; VYDAC ), using the following gradient in which H 2 O was solvent A and methanol was solvent B: 0 -10 min, 0% B; 10 -20 min, 0 -30% B; 20 -100 min, 30 -100% B. The product was eluted at 65.4 min to yield 92.4 mg (60.1%) of compound 5a. 1 N-(NЈ-Methyl-NЈ-biotinylglycyl)12-aminoundecanoic acid (5b) was prepared using a method analogous to that for compound 5a.
N-Hydroxysuccinimide ester of 5a (6a). Compound 5a (9.8 mg; 1.9 mol) and N-hydroxysuccinimide (2.2 mg; 1.9 mol) were dissolved in 100 L of anhydrous DMF, and dicyclohexylcarbodiimide (3.9 mg; 1.9 mol) was added last. The reaction was allowed to proceed for 60 h at room temperature in the dark with continuous stirring. The crude product was purified by flash chromatography on silica gel (chloroform-methanol, 15:1-12:1 by volume) to yield 9.8 mg (84%) of compound 6a. 1 The N-hydroxysuccinimide ester of 5b (compound 6b) was prepared using a method analogous to that for compound 6a.
ASM substrate conjugate (7) . Sphingosylphosphoryl choline (2.5 mg; 5.4 mol) and 6a (3.3 mg; 5.4 mol) were dissolved in 150 L of anhydrous DMF, and 2.5 L of diisopropylethylamine was added. The reaction was allowed to proceed for 2 days at room temperature. The product was purified by HPLC (protein & peptide C 18 column; cat. no. 218TP1010; VYDAC), using the following gradient in which H 2 O was solvent A and methanol was solvent B: 0 -10 min, 0% B; 10 -11 min, 0 -20% B; 11-60 min, 20 -100% B; 60 -90 min, 100% B. The product was eluted at 75.5 min to yield 3.6 mg (69%) of compound 7. N-(p-Toluenesulfonyl)glycine-1-13 C (9). Glycine-1-13 C (2.28 g; 30 mmol) was dissolved in 25 mL of 3 mol/L sodium hydroxide, and p-toluenesulfonyl chloride (6.29 g; 33 mmol) was added. The mixture was stirred at room temperature for 4 h. The solution was then acidified to pH 1 with 6 mol/L hydrochloric acid. The crystals were collected, dried, and flash-chromatographed on a silica gel column, using ethyl acetate-CHCl 3 (3:2 by volume) containing 20 mL/L acetic acid as the mobile phase, to yield 4.42 g (64%) of compound 9. 1 N- (Methyl-d 3 ) glycine-1-13 C (11). A solution of compound 10 (2.97 g; 12 mmol) in 30 mL of hydrogen bromidesaturated glacial acetic acid was heated at 80°C under argon for 3 h. The mixture was poured into 120 mL of water and washed with ether; the aqueous solution was then evaporated under reduced pressure to dryness. The solid residue was recrystallized from acetone to give 1.88 g (90%) of compound 11. 1 H-NMR (500 MHz, CD 3 OD) gave the following results: 3.96 -3.90 (d, 2H). (12) . To an ice-cold solution of compound 11 (1.39 g; 8 mmol) in 15 mL of dry methanol was added dropwise 0.3 mL of SOCl 2 . The solution was then refluxed for 4 h. The solvent was evaporated under reduced pressure, and traces of SOCl 2 were removed by adding benzene (10 mL) and repeating the evaporation three times. Without further purification, the product was used for the following step with an estimated yield of 90%. (13 and  14) . The desired compounds were made using the same procedure to make compounds 7 and 8 except that sphingosine was used in place of sphingosylphosphoryl choline and psychosine, respectively. The structures of compounds 13 and 14 were confirmed by 1 H-NMR and ESI-MS.
N-(Methyl-d 3 )glycine-1-13 C methyl ester
ASM and GCG product conjugate internal standards
asm assay
To prepare the cell homogenate, fibroblasts were thawed, suspended in 100 L of purified water (MilliQ; Millipore Inc.) in a 1.7-mL polypropylene microcentrifuge tube and lysed by two 15-s bursts of pulsed (20% cycle) ultrasound (Model W-225 sonicator; Ultrasonics, Inc.; output control setting 2, stainless steel probe) while cooling the tube in an ice bath. The number of fibroblasts used was sufficient to give a protein concentration of 2-5 g/L of lysate when assayed using the Bradford assay (Bio-Rad) calibrated with bovine serum albumin. The lysate was kept on ice and used within 15 min.
A mixture of 15 nmol (14 g) of ASM substrate conjugate 7 and 75 g of Triton X-100 in methanol was placed in a 1.7-mL polypropylene microcentrifuge tube, and the solvent was evaporated under a stream of nitrogen. After drying, 75 L of 1.0 mol/L acetate buffer (pH 5.0) was added, and the tube was placed in a bath sonicator (Model G112SP1T; Lab Supplies Inc.) for 1.5 min. Fibroblast lysate containing 30 -120 g of protein was added, and the total volume was adjusted to 0.15 mL with MilliQ water. The sample was incubated at 37°C for 1-4 h.
After incubation, the reaction was quenched by adding methanol (0.45 mL), and 1-4 nmol (0.7-3 g) of internal standard 13 was added as a 0.5 mmol/L solution in methanol. The solvent was removed under reduced pressure (Speed-Vac; Savant Instruments), the residue was redissolved in methanol (0.15 mL), and insoluble debris was removed by centrifugation (ϳ12 000g for 1 min). The supernatant (100 L) was transferred to a Microbiospin column (Bio-Rad) containing immobilized streptavidin (Immunopure; Pierce; 5 nmol of biotin binding capacity; suspension supplied by manufacturer). The column was gently rocked at room temperature for 2 min and then centrifuged (ϳ6000g for 1 min). The gel was washed by rocking for 2 min with methanol-water (1:1 by volume; 150 L) and centrifuged as above. This wash step was repeated once followed by three washes with MilliQ water (150 L). To release the conjugates, 80 L of a 0.5 mmol/L solution of biotin ethyl ester in methanol was added, and the spin column was capped and incubated at 4°C for 6 h. The column was centrifuged as above, and the eluate was mixed with 20 L of 20 mmol/L ammonium acetate in methanol to facilitate ESI-MS.
gcg assay A mixture of GCG substrate (14 g; 15 nmol), sodium taurocholate (100 g; 186 nmol), and oleic acid (20 g; 70 nmol) in chloroform-methanol (2:1 by volume) was placed in a 1.7-mL polypropylene microcentrifuge tube, and the solvent was evaporated under a stream of nitrogen. After drying, 75 L of a 0.2 mol/L citrate-phosphate buffer (pH 4.2) was added, and the tube was sonicated for 2 min as for the ASM assay. Typically, 20 -100 g of fibroblast protein (cell homogenate prepared as for the ASM assay) was used per incubation. The total volume was adjusted to 0.15 mL with MilliQ water, and the sample was incubated at 37°C for 1-4 h. Reactions were worked up exactly as described for the ASM assay using 1-4 nmol (0.7-3 g) of the GCG internal standard 14.
esi-ms analysis
Mass spectra were obtained on a Bruker-Esquire ion trap mass spectrometer. Samples were infused by flow injection at 1 L/min and ionized in a standard orthogonal Bruker ionizer. The mass spectrometric conditions were as follows: electrospray capillary, 4000 V; end-plate, 500 V; transfer capillary, 70 V; drying gas temperature, 250°C; skimmer 1, 20 V; skimmer 2, 6.0 V; octopole I, 3 V; octopole II, 1 V; octopole radiofrequency, 100 V; peak-topeak lens I voltage, Ϫ5 V; lens II voltage, Ϫ50 V. Mass spectra were obtained by ejecting trapped ions in the range of m/z 700-1000 for ASM assays and m/z 750 -850 for GCG assays. Approximately 100 scans were accumulated and averaged to provide the spectra used for quantification. The relevant regions in the ESI mass spectra are shown in Figs. 1 and 2 and discussed below.
Results and Discussion
The activities of ASM and GCG toward the synthetic substrate conjugates were tested with cell homogenates from cultured skin fibroblasts from anonymous healthy individuals. ASM activity was measured by the formation of the product, which was detected in the ESI mass spectrum as the corresponding peak of the protonated product conjugate and its naturally occurring isotope satellites at m/z 794.9 -796.9 (Fig. 1, bottom panel) . The peaks at m/z 959.7-961.7 correspond to the unreacted substrate conjugate, whereas the peaks at m/z 798.8 -800.8 are from the heavy isotope-labeled internal standard. The peaks at m/z 816.8 and 820.8 in Fig. 1 are from nonlabeled and heavy isotope-labeled product conjugates, respectively, ionized by attachment of a sodium ion. Both the (M ϩ H) ϩ and (M ϩ Na) ϩ peaks can be used for quantification; in the present analyses, the more abundant (M ϩ H) ϩ peaks were measured. Likewise, the GCG activity was determined from the ESI mass spectrum (Fig. 2, bottom  panel) , which showed the peaks of the enzymatic product at m/z 780.9 -782.9 and those of the labeled internal standard at m/z 785.0 -787.0. The ESI mass spectra demonstrate that the mass shift of 4 mass units in the internal standards attributable to stable-isotope labeling was sufficient to prevent overlap with the peaks of the enzymatic products.
Quantification of the data obtained from the ESI mass spectra provided activities in nmol ⅐ mg Ϫ1 ⅐ h Ϫ1 for both ASM and GCG as shown in Table 1 . The measurements showed ϳ20% variability among the healthy individuals for both ASM and GCG activities. In contrast, the affected patients showed only residual activities of ASM (ϳ8% of mean normal activity) and GCG (ϳ3% of mean normal activity). This is evident from the corresponding ESI mass spectra ( Figs. 1 and 2 , top panels), which displayed much lower formation of the enzymatic products. The analysis of cells from affected patients also showed that deficiencies in the activities of ASM and GCG enzymes were not cross-correlated (Table 1) . This is evident from the ASM activities in cell lysates from two GCGaffected patients, which were within 1 SD of the mean of activities measured for healthy individuals. Likewise, GCG activities in cell lysates from patients affected with ASM were within 1.2 SD of the mean of activities for healthy individuals. These results are consistent with the previous studies of Wenger et al. (5 ) , who found no significant decrease of GCG activity in cell homogenates from patients with Niemann-Pick disease.
Enzymatic rates were also measured as a function of the total cell protein used. Both the ASM and GCG rates showed linear responses to the amount of protein from cell homogenate as documented for ASM ( Fig. 3 , top panel) and GCG (Fig. 4, top panel) . The correlation coefficients (r 2 ) for both the ASM and GCG determinations were 0.998. The mean ASM activity toward the biotinylated substrate conjugate (53 Ϯ 12 nmol ⅐ mg protein Ϫ1 ⅐ h Ϫ1 ) was somewhat lower than that reported by Wenger (6 ) for 14 C-labeled sphingomyelin (83 Ϯ 23 nmol ⅐ mg Ϫ1 ⅐ h Ϫ1 ). Detection limits achieved by the ESI-MS assays can be estimated from the amount of cellular protein used and the analyte and background peak intensities in the ESI mass spectra. The ESI-mass spectrum shown in the bottom panel of Fig. 1 was obtained by injecting 5-10 L (5-10% of the 100-L total volume) of the productconjugate solution used for assaying 30 g of protein from Ϸ10 5 cells. Pooling of this product-conjugate solution permitted 10 -20 replicate analyses to be made per assay. The product-conjugate solution volume could be readily decreased to 5 L by carrying out the bioaffinity capture and release in a capillary microvessel (16 ) , which reduces the total cell protein needed per assay by 10-to 20-fold. The m/z 780 -790 region, which contains the peaks of the ASM product and internal standard, was free of interfering peaks, providing a low background.
The ESI-MS data showed that at a background variation of 3, a 16-fold reduction in the product conjugate concentration obtained from the assay would still allow unambiguous detection of enzyme activity Ͼ0.3 nmol ⅐ mg Ϫ1 ⅐ h Ϫ1 . Hence, the product-conjugate solution from the microvolume assay could be diluted as needed for replicate injections and ESI-MS measurements. We estimate that ESI-MS could allow assays using Ͻ2 g of protein, corresponding to Ͻ8000 cells, to be carried out routinely (16 ) . Because 2 ϫ 10 6 cells typically are harvested per cell culture, these can be pooled for multiplex assays of Ͼ200 different enzymes using ESI-MS.
Detection of the GCG product and internal standard was accompanied by somewhat higher background peaks at adjacent m/z values that appeared consistently in replicate analyses (Fig. 2) . The origin of the background peaks was not determined. Although the background peaks did not overlap directly with the peaks of the analytes, they could provide an increased background, leading to higher detection limits. Nevertheless, the ESI-MS analysis achieved clear distinction between the GCG product obtained from cell lysates from healthy patients (Fig. 2, bottom panel) and that obtained from cell lysates from affected patients (Fig. 2, top panel) . The mean activity of GCG from skin fibroblasts toward the biotinylated substrate conjugate (5.3 Ϯ 1 nmol ⅐ mg Ϫ1 ⅐ h Ϫ1 ) was comparable to that reported for radiolabeled galactosyl ceramide (4.7 nmol ⅐ mg protein Ϫ1 ⅐ h Ϫ1 ) (5 ) .
Formation of both the ASM and GCG products showed a linear dependence on the incubation time ( Figs. 3 and 4 , bottom panels). These results indicate that the total amount of enzymatic product that was generated by either assay could be varied by adjusting the incubation time to facilitate analysis and also that the initial enzymatic reaction velocities were being measured.
In conclusion, we demonstrate the use of ESI-MS for assaying the lysosomal enzymes ASM and GCG in cultured skin fibroblasts. This new method does not require radioactive substrates, achieves product speciation with low backgrounds, and provides detection limits comparable to those from assays using radioactive labels. Because quadrupole ion trap and other types of compact mass spectrometers are increasingly used in biomedical research, ESI-MS-based assays can provide convenient alternatives to the currently used methods. Perhaps most importantly, because enzymatic products are resolved on the basis of their m/z ratios, it is possible to develop protocols that assay multiple enzymes in a single analysis. This can be done by multiplexing the assay procedures (16 ) or by multiplexing mass spectrometric analyses by combining eluates from separate enzymatic assays.
